Lexaria Bioscience Corp. (LEXX)

Market Cap	27.85M
Revenue (ttm)	385,995
Net Income (ttm)	-5.45M
Shares Out	12.38M
EPS (ttm)	-0.68
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	123,825
Open	2.340
Previous Close	2.340
Day's Range	2.220 - 2.410
52-Week Range	0.649 - 6.850
Beta	0.95
Analysts	Strong Buy
Price Target	12.00 (+433.33%)
Earnings Date	Apr 9, 2024

About LEXX

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 5
• Stock Exchange: NASDAQ
• Ticker Symbol: LEXX

Financial Performance

In 2023, LEXX's revenue was $226,208, a decrease of -11.43% compared to the previous year's $255,397. Losses were -$6.66 million, -8.31% less than in 2022.

Analyst Forecast

According to one analyst, the rating for LEXX stock is "Strong Buy" and the 12-month stock price forecast is $12.0.

Price Target

$12.0

(433.33% upside)

Analyst Consensus: Strong Buy